Copy Number Gain of 11q13.3 Genes Associates with Pathological Stage in Hypopharyngeal Squamous Cell Carcinoma by Pattle, Samuel B et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copy Number Gain of 11q13.3 Genes Associates with
Pathological Stage in Hypopharyngeal Squamous Cell
Carcinoma
Citation for published version:
Pattle, SB, Utjesanovic, N, Togo, A, Wells, L, Conn, B, Monaghan, H, Junor, E, Johannessen, I, Cuschieri,
K & Talbot, S 2017, 'Copy Number Gain of 11q13.3 Genes Associates with Pathological Stage in
Hypopharyngeal Squamous Cell Carcinoma' Genes, Chromosomes and Cancer, vol. 56, no. 3, pp. 185-
198. DOI: 10.1002/gcc.22425
Digital Object Identifier (DOI):
10.1002/gcc.22425
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Genes, Chromosomes and Cancer
Publisher Rights Statement:
Author's final peer-reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Copy Number Gain of 11q13.3 Genes Associates with Pathological Stage in 
Hypopharyngeal Squamous Cell Carcinoma 
 
Samuel B Pattle1, Natasa Utjesanovic1, Athena Togo2, Lucy Wells3, Brendan Conn4, Hannah 
Monaghan4, Elizabeth Junor3, Ingolfur Johannessen5, Kate Cuschieri6, Simon Talbot1 
1 Division of Infection & Pathway Medicine, The University of Edinburgh 
2 Department of Otolaryngology, The Laurieston Building, NHS Lothian 
3 The Edinburgh Cancer Centre, Western General Hospital, NHS Lothian 
4 Department of Pathology, Royal Infirmary of Edinburgh, NHS Lothian 
5 Department of Laboratory Medicine, Royal Infirmary of Edinburgh, NHS 
6 Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian 
Correspondence to : 
Samuel B Pattle 
Division of Infection & Pathway Medicine, The University of Edinburgh, The Chancellor’s Building, 
49 Little France Crescent, Scotland, EH16 4SA 
Tel +447770 180185  Email v1spattl@exseed.ed.ac.uk 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/gcc.22425
This article is protected by copyright. All rights reserved.
   
2 
 
ABSTRACT 
Squamous cell carcinomas of the hypopharynx (HPSCC) and oropharynx (OPSCC) have markedly 
different patient outcomes. Differences in HPV prevalence between these two patient groups may 
account for some of this difference, but other molecular markers of prognosis or pathological 
phenotype have not been established. Copy number gain of oncogenes is a well-established 
molecular change contributing to HNSCC development. Quantitative PCR was used to explore 
copy number gains of specific genes (3q - PIK3CA, TP63; 11q13.3 - CCND1, ANO1) in tumour 
DNA recovered from HPSCC (n=48) and OPSCC (n=52) patients. Associations between copy 
number gain, patient demographics, HPV/p16INK4a status and pathological stage were examined. 
HPV/p16 prevalence in HPSCC and OPSCC groups was 2.1% and 46.0% respectively. HPSCCs 
had frequent gains of CCND1 (56.3%) and ANO1 (56.3%) but few gains of PIK3CA (6.3%). By 
contrast, OPSCCs had significantly fewer CCND1 (23.1%) and ANO1 (17.3%) gains, and 
significantly more PIK3CA (26.9%) gains. A mutually exclusive relationship between HPV/p16 and 
11q13.3 gains was observed in OPSCCs, while PIK3CA and TP63 gains were similar across HPV-
associated and smoking/alcohol-associated patients. ANO1 gain was significantly linked to tumour 
pathology in HPSCC, associating with nodal metastasis and smaller and less invasive tumours at 
presentation (p=0.010). Our results provide a convincing link between a specific molecular change 
and disease phenotype that appears unique to our HPSCC population, supporting a model of 
11q13.3 in promoting metastatic disease progression in HNSCC, and suggest a role for ANO1 as a 
molecular marker of metastatic disease. 
244 words 
KEY WORDS Hypopharyngeal Carcinoma, Oropharyngeal Carcinoma, 11q13.3, HPV/p16INK4a, 
copy number gain, lymph node metastasis 
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INTRODUCTION 
Head and neck cancers remain a major cause of cancer-associated morbidity and mortality 
worldwide. Squamous cell carcinomas (HNSCC, accounting for more than 90% of head and neck 
cancers) are now recognised as having at least two distinct aetiological origins. Tobacco and 
alcohol exposure account for 70-80% of cases, but a growing subset in younger patients without 
this typical risk profile and associated with high risk Human Papillomavirus (HPV) infection are 
increasingly common in some populations (Gillison et al., 2008; Junor et al., 2012). Crucially, these 
different patient subsets have distinct clinical outcomes - with HPV-associated disease fairing 
favourably in treatment response, recurrence and survival (Ragin et al., 2007; Klussmann et al., 
2007; Fakhry et al., 2008; Junor et al., 2012; Salazar et al., 2014), providing the basis for a risk 
stratification process based on the molecular detection of HPV in tumours. Guidelines for HPV 
annotation of head and neck tumours have been developed for the UK by the Royal College of 
Pathologists (Helliwell et al., 2013), although currently only for OPSCC patients where the link 
between HPV and prognosis is most apparent. To date, HPV and its co-marker p16INK4A are the 
only biomarkers in widespread clinical use in the management of HNSCC. 
 
Large-scale next generation sequencing (NGS) projects have profiled HNSCC across multiple 
molecular and cellular levels, and many themes from early cytogenetic work (including broad, 
binary distinctions between smoking/alcohol and HPV-associated disease) have now been 
expanded upon. The consistent observation in early work of a mutually exclusive relationship 
between amplification of the 11q13.3 chromosomal band (found in high frequency across HNSCC, 
and other cancers) and the presence of HPV in tumours remains one of the most striking 
differences observed within HNSCCs (Smeets et al., 2006; Ragin et al., 2006; Klussmann et al., 
2009; Lechner et al., 2013; Seiwert et al., 2015). This separation may be attributable to the 
divergent mechanisms by which chemical carcinogens (via genetic amplification and consequent 
over-expression of Cyclin D1 gene CCND1 within the 11q13.3 amplicon - often in combination with 
genetic or functional loss of restriction point Cyclin Kinase Inhibitor p16INK4A) and HPV (via HPV 
oncoproteins E6 and E7) achieve dysregulation of the cell cycle. In contrast, certain genetic 
changes have emerged as common to both HPV and smoking/alcohol-associated HNSCC. For 
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example, mutation, amplification and over-expression of elements of the PI3 kinase pathway (in 
particular the p110 catalytic subunit gene PIK3CA at 3q26.3) have been consistently observed 
across both aetiological groups (Smeets et al., 2006; Wilting et al., 2009; Lechner et al., 2013; 
Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 2015). 
 
Integrated NGS analysis has also expanded upon binary aetiological classification, with new sub-
classes now defined by broad common patterns of copy number change, mutation, transcription 
and cellular features (now including atypical, classical, mesenchymal/inflammatory and basal 
classes, as described in Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 
2015). Some key areas remain under-explored, however, including whether common specific 
changes underpin a ‘switch’ from locally invasive to nodal or distant metastatic disease, or 
underpin the markedly differing outcomes of tumours from different anatomical sites. Any such 
markers have the potential to be exploited as risk stratification tools, or new therapeutic targets. 
 
In this study, we aimed to explore how copy number gain of HNSCC-associated genes might differ 
between oropharyngeal (OPSCC) and hypopharyngeal (HPSCC) tumours, and how the observed 
genetic changes might link to clinico-pathological features across the two patient groups. Although 
less common than other head and neck tumours, HPSCCs have some of the worst outcomes of 
head and neck tumours (Pulte et al., 2010), and remain relatively under-researched from a 
molecular perspective. We developed a qPCR assay to determine copy number gain in specific 
genes from the commonly amplified 3q arm (PIK3CA, TP63) and 11q13.3 amplicon (CCND1, 
ANO1). We used this assay to explore the frequency of copy number gains in HPSCC and OPSCC 
tumours, and using linked patient data we examined the relationships between the observed copy 
number gains and clinico-pathologic characteristics of the two patient groups. 
 
MATERIALS AND METHODS 
Patients 
Patients referred to the Edinburgh Cancer Centre with histologically confirmed HPSCC (2003-2012) 
or OPSCC (2011 to 2012) were identified and relevant demographic and clinico-pathologic data 
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extracted from electronic and paper records. Current smokers were defined as patients smoking at 
presentation, ex-smokers as patients who reported stopping smoking prior to presentation. Social 
drinkers were defined as patients drinking within recommended weekly alcohol limits (males <18 
units, females <14 units), current or past heavy drinkers as patients drinking in excess of these 
limits at, or prior to presentation, respectively. 
 
HPV & p16 testing, genomic DNA extraction 
Sections of formalin fixed paraffin embedded (FFPE) tumour blocks (approved for use by the South 
East of Scotland BioResource - project reference SR-090) were reviewed and selected by a 
pathologist to confirm histological diagnosis. Immunohistochemistry (IHC) for p16 was carried out 
on 3µm sections using a monoclonal antibody to p16 (CINtec Histology, mtm Laboratories) on a 
Leica Bond III automated immunostainer. IHC for p16 was scored independently by two 
pathologists, with double review of any cases where there was not consensus, and considered 
positive if there was strong diffuse nuclear and cytoplasmic staining present in >70% of malignant 
cells (Singhi et al., 2010). 
 
Tumour genomic DNA was extracted from corresponding sections of FFPE tissue blocks, and from 
FFPE blocks of normal tonsil tissue (as reference human genomic DNA for qPCR and copy 
number calculation) as described previously (Junor et al., 2012). Tumour sections comprised 
approximately 66% tumour tissue in the majority of cases. HPV testing was performed on extracted 
genomic DNA using the Optiplex HPV Genotyping Assay (Diamex, Heidelberg, Germany), as 
described previously (Cuschieri et al., 2013). DNA extracts were further purified and concentrated 
by ethanol precipitation and re-suspension in nuclease-free water, and samples selected for qPCR 
based on amount of DNA available (>30ng total DNA) and spectrophotometric quality 
(260nm/280nm absorption >1.8; 260nm/230nm absorption >2.0). Of 87 HPSCC FFPE samples 
tested for HPV, 48 were found to have sufficient amounts & quality of DNA for qPCR, and were 
included in the final genetic amplification analysis (HPSCC n=48). Of 60 OPSCC FFPE samples 
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tested for HPV, 52 were found to have sufficient amounts & quality of DNA for qPCR (OPSCC 
n=52). 
 
Reference & target site selection for qPCR 
Target sites for examining copy number gain were selected in genes commonly reported as 
amplified in HNSCC – two genes on the 3q chromosomal arm (PIK3CA, TP63) and two genes in 
well-characterised 11q13.3 amplicon (CCND1, ANO1). As a reference gene we selected a 
chromosomal region infrequently reported as amplified or deleted across the literature - 2p23 - and 
within this, the EIF2B4 gene, given its putative constitutive role (initiation of protein translation), no 
reported involvement in malignant disease, and no current reports of copy number variation. 
Primer pairs were selected using the Primer3 software tool, with specificity confirmed using the 
BLAST search tool. Reference and target amplicons were generated using PCR with pooled 
human genomic DNA (Promega) as template (reaction conditions and primers shown in 
Supplemental Materials S1). PCR products were cloned into the Promega pGem-T-easy vector (as 
per manufacturer’s instructions). Sanger sequencing was used to confirm plasmid amplicon 
specificity. 
 
qPCR & copy number determination 
qPCR was performed using the Maxima SYBR green master mix (Thermo Scientific) and the 
Stratagene Mx3000p thermos-cycler (Agilent Technologies). Reaction conditions were optimised 
(Supplemental Materials S1) and product specificity assessed using melt curve analysis, using 
commercial human genomic DNA as substrate. As a valid reference sample for copy number 
determination in tumour DNA, qPCR was performed and reference copy number values derived 
from a pool of human genomic DNA extracted from 31 FFPE tissue blocks of normal tonsils with 
qPCR-confirmed normal copy number (using the ddCt method with above mentioned commercial 
human genomic DNA as reference). These samples were deemed analogous to the FFPE tumour 
collection with regard to storage conditions, sample age (2002-2012) and extraction procedure, 
providing a more valid calibrator for tumour copy number calculation. qPCR for each target and 
reference gene was performed in replicate on tumour (sample) and tonsil (reference/calibrator) 
Page 6 of 33
John Wiley & Sons
Genes, Chromosomes & Cancer
This article is protected by copyright. All rights reserved.
   
7 
 
genomic DNA. Estimated copy number of target genes in tumour samples was evaluated by 
relative quantitation using the ddCt method (as described previously in Ginzinger et al., 2000, 
Huang et al., 2002) and final copy number calls assigned based on an assumed normal copy 
number of two in the pooled normal tonsil DNA (as confirmed by comparison to commercially 
available normal human genomic DNA). 
 
Analysis 
To explore relationships between copy number gain, risk factors and tumour stage, patients were 
grouped according to the presence or absence of target site copy numbers greater than or equal to 
four (to account for possible stromal/normal tissue contamination in FFPE tumour samples, as 
described previously in Huang et al., 2006). Patient groups were compared by tumour site (HPSCC 
vs OPSCC) and HPV/p16 status (HPV negative/p16 negative vs HPV positive/p16 negative vs 
HPV negative/p16 positive vs HPV positive/p16 positive). Presence of any high risk HPV type in a 
sample was used to classify patients as “HPV positive”, and for purposes of univariate analysis, 
patients were grouped according to their combined HPV and p16 status (HPV positive/p16 positive 
versus not HPV positive/p16 positive, including HPV positive/p16 negative, HPV negative/p16 
positive and HPV negative/p16 negative – referred to collectively as “HPV/p16 negative” 
henceforth). Patients were then grouped by presence or absence of copy number gain at target 
sites within PIK3CA, TP63, CCND1 or ANO1, and association between gains and clinico-
pathologic features (sex, smoking, drinking, TNM stage, HPV/p16 status) were examined using 
univariate analysis. Pearson’s Chi-square (unless otherwise stated) or Fisher’s Exact Test (‘f’) 
were used for univariate analysis between patient groups; age differences were examined using 
Student’s t-test; analysis was performed using IBM SPSS v22. 
 
RESULTS 
Demographics, risk factors and pathological stage across anatomical and HPV/p16 groups 
Comparing patients by anatomical site (Table 1), HPSCC and OPSCC patients differed 
significantly with regard to sex (p<0.001; HPSCCs predominantly male, compared to relative 
gender equivalence amongst OPSCC), smoking (p=0.002; HPSCC predominantly current 
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smokers, OPSCC predominantly never or ex-smokers) and heavy drinking (p=0.012; almost half 
HPSCCs having ex- or current history of heavy drinking, and twice as likely to have heavy drinking 
history than OPSCCs). 
 
The two anatomical groups differed significantly with regard to HPV/p16 status (p<0.001) - only 
one HPSCC tumour was confirmed as HPV positive/p16 positive (all other tumours were HPV 
negative/p16 negative), this single sample was HPV-18 positive. In contrast 23 of 52 (44.2%) 
OPSCC tumours were confirmed as HPV positive/p16 positive – with HPV-16 being the 
commonest high-risk type. HPV and p16 status were significantly associated (p<0.001) – only four 
tumours were HPV positive/p16 negative and two HPV negative/p16 positive. Comparing the 
HPV/p16 negative patient groups across the two anatomical sites (i.e. HPV/p16 negative HPSCC 
vs HPV/p16 negative OPSCC, Table 2) found these patient groups to be more similar with regard 
to smoking and drinking history - the two groups remained distinct only with regard to sex 
(p=0.001). 
 
Comparing patients (across both anatomical sites) by HPV/p16 status highlighted significant 
differences in risk factor history between these two aetiological groups (Table 3). Only one of 24 
(4.2%) HPV/p16 positive patients was a current smoker, compared to 46 of 74 (63.9%) HPV/p16 
negative patients (p<0.001). Similarly only two (9.1%) HPV/p16 positive patients were past or 
current heavy drinkers, compared to 32 (45.7%) HPV/p16 negative patients (p=0.002). 
Pathological stage at presentation also differed between HPV/p16 groups – HPV/p16 positive 
primary tumours were more likely to be lower T stage (18 of 24 (75.0%) HPV/p16 positive tumours 
being T1-3 at presentation, compared to 38 of 74 (51.4%) HPV/p16 negative tumours, p=0.034), 
and more likely to be node metastasis positive at presentation (23 of 24 (95.8%) HPV/p16 positive 
tumours being node positive at presentation, compared to 49 of 74 (66.2%) HPV/p16 negative 
tumours, p=0.004). Combining T and N stage found HPV/p16 positive patients significantly more 
likely to present with smaller or less locally invasive primary but with node positive disease (17 of 
24 (70.8%) HPV/p16 positive patients T1-3/N positive at presentation, compared to 25 of 74 
(33.8%) HPV/p16 negative patients; p=0.001). 
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Frequency and pattern of target copy number gains across anatomical and HPV/p16 groups 
The frequency and pattern of copy number gains at target sites within PIK3CA, TP63, CCND1 and 
ANO1 genes differed significantly across anatomical and HPV/p16 groups (Tables 1-3; Figure 1). 
Comparing anatomical groups (Table 1; Figure 1i), copy number gain of PIK3CA was significantly 
more common in OPSCC patients (14 of 52 (26.9%) OPSCCs having PIK3CA gain, compared to 
only three of 48 (6.3%) HPSCCs; p=0.006). By contrast, copy number gains of CCND1 and ANO1 
were significantly more common in HPSCC patients (27 of 48 (56.3%) of HPSCCs having CCND1 
gain, 27 of 48 (56.3%) having ANO1 gain, compared to 12 (23.1%) and 9 (17.3%) of 52 OPSCCs 
respectively; p<0.001 in both instances). Frequency of TP63 copy number gain was similar across 
both HPSCC (9 of 48 (18.8%)) and OPSCC (10 of 52 (19.2%)) groups (p=0.951). 
 
Grouping patients by HPV/p16 status revealed significant differences in CCND1 and ANO1 copy 
number gain frequency (Table 2; Figure 1ii). No HPV/p16 positive tumours were found to have 
ANO1 gain (compared to 37 of 74 (50.0%) HPV/p16 negative tumours), while only one of 24 
(4.2%) HPV/p16 positive tumour had CCND1 copy number gain (compared to 35 of 74 (47.3%) 
HPV/p16 negative tumours)(p<0.001 in both instances). Frequency of copy number gains at 
PIK3CA and TP63 target sites were not significantly different between HPV/p16 positive and 
negative groups (11 of 74 (14.9%) HPV/p16 negative tumours had PIK3CA gains compared to 6 of 
24 (25.0%) HPV/p16 positive tumours (p=0.255), and 15 of 74 (20.3%) HPV/p16 negative tumours 
had TP63 gains compared to 4 of 24 (16.7%) HPV/p16 positive tumours (p=0.698). 
 
Comparing the HPV/p16 negative subsets of HPSCC and OPSCC (Table 3; Figure 1iii), PIK3CA 
copy number gain remained significantly more common in OPSCCs (8 of 27 (29.6%)) than 
HPSCCs (3 of 47 (6.4%))(p=0.01f). A higher frequency of CCND1 and ANO1 copy number gains in 
HPSCC tumours was again apparent - 10 of 27 (37.0%) HPV/p16 negative OPSCCs had CCND1 
gains, and only eight of 27 (29.6%) had ANO1 gains, compared to 27 of 47 (57.4%) HPV/p16 
negative HPSCCs with CCND1 or ANO1 gains (p=0.091 and p=0.021 respectively). 
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Synchronous copy number gains were observed with ANO1 and CCND1 in both anatomical 
groups (24 HPSCC tumours and 9 OPSCC tumours harbouring both CCND1 and ANO1 gains 
together; p<0.001 in both instances). TP63 gains were more frequent in HPSCCs and OPSCCs 
with ANO1/CCND1 gains, but these results were not statistically significant. In HPSCC, PIK3CA 
gain was mutually exclusive to ANO1 gain (p=0.077f) – this pattern was not observed in OPSCC. 
 
Association of target copy number gains with pathological stage 
Grouping patients by the presence or absence of copy number gains at target sites revealed a 
distinct pattern of association between ANO1/CCND1 gain and pathological stage in HPSCC 
patients, but not in OPSCC patients (Tables 4, 5 & 6; Figure 2). In HPSCC patients, copy number 
gains of ANO1 were significantly associated with smaller or less invasive (T1-3 vs T4) primary 
tumours (18 of 25 (72.0%) T1-3 HPSCCs had ANO1 gain, compared to 9 of 23 (39.1%) T4 
tumours; p=0.022), and with node positive disease at presentation (22 of 33 (66.7%) node positive 
HPSCCs had ANO1 gain, compared to 5 of 15 (33.3%) node negative tumours; p=0.031)(Figure 
2a). This association was also significant in smaller (T1-3) / node positive HPSCC tumours (15 of 
19 (78.9%) T1-3/node positive HPSCCs had ANO1 gain, compared to 12 of 29 (41.4%) of T4 or 
node negative T1-3 tumours; p=0.010). Similar (but non-significant) associations between gains of 
CCND1 and TP63 and smaller, node positive HPSCC tumours were also observed (Table 1), 
though the majority of tumours with copy number gains at CCND1 (24 of 27 (88.9%)) and TP63 (7 
of 9 (77.8%)) target sites also had ANO1 gains. No significant pattern of association between 
ANO1 copy number gain (or any other target site) and pathological stage was found in OPSCC 
tumours, regardless of HPV/p16 status (Tables 2 & 3; Figure 2b). No significant patterns of 
association between any copy number gain and risk factor history or patient demographic were 
found in any patient group (by anatomical site or HPV status). 
 
DISCUSSION 
The advent of scalable next generation sequencing technologies brings with it the potential to 
stratify HNSCCs into new subclasses, framed by tumour aetiology (HPV vs smoking/alcohol) but 
defined by distinct common patterns spanning multiple levels of molecular and cellular change 
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(Lechner et al., 2013; Walter et al., 2013; Cancer Genome Atlas Network, 2015; Keck et al., 2015; 
Seiwert et al., 2015). In the present study, we targeted one aspect of genetic change that can 
underlie malignant progression - copy number gain - at specific sites in four genes strongly 
associated with head and neck cancer – PIK3CA, TP63, CCND1 and ANO1. We find distinct 
frequencies and patterns of copy number gain across different anatomical and HPV/p16 patient 
subsets, with PIK3CA gains significantly more common in OPSCC, and CCND1 and ANO1 gains 
significantly more common in HPSCC. Crucially, we find distinct associations between these 
molecular changes and pathological features amongst different tumour subgroups, suggesting a 
possible molecular-pathogenic link between copy number gains in the 11q13.3 band (ANO1, 
CCND1) and early nodal metastasis in HPSCC. 
 
In our study, the finding of a subset of HPSCCs with ANO1/CCND1 copy number gains that 
present with node positive and smaller, less locally invasive primary tumours provides a convincing 
link between a specific molecular change and disease phenotype amongst a specific subset of 
HNSCCs. Of 27 HPSCCs found to have ANO1 copy number gains, 22 (81.5%) were node-positive 
at presentation. This finding could suggest a direct contributing role for ANO1 and/or CCND1 copy 
number gain (likely in the form of the well-documented high level amplification of the 11q13.3 band 
leading to over-expression of these and/or other amplicon-resident genes) toward an early ‘switch’ 
from local invasion to nodal metastasis in HPSCC, resulting in the ‘smaller primary / node positive’ 
association observed. Our findings in HPSCC are consistent with other models examining links 
between 11q13.3 amplification and metastatic potential in HNSCC (Muller et al., 1994; 
Welkoborsky et al., 2000; Miyamoto et al, 2002; Hermsen et al., 2005; Myo et al., 2005; Rothschild 
et al., 2006; Ayoub et al., 2010; Sugahara et al., 2011; Pattje et al., 2013; van Kempen et al., 
2015). 
 
Several genes within the 11q13.3 amplicon have been proposed as drivers and markers of 
recurrence and metastasis, including ANO1 and CCND1. Ano1 (a transmembrane calcium-
activated chloride channel) has been suggested to contribute to malignant progression by 
stabilising EGFR at membrane surfaces (thereby promoting mitogenic stimulus to the cell) 
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(Britschgi et al., 2013; Bill et al., 2015), but may also directly engage with MAP kinase pathways to 
promote growth and survival (Duvvuri et al., 2012; Sui et al., 2014). Although it is often reported in 
association with metastasis and recurrence in translational studies, other studies have reported 
effects on proliferation and local invasion (Ruiz et al., 2012; Shiwarski et al., 2014; Jia et al., 2015), 
suggesting the tumourigenic functions of Ano1 may be more complex than a ‘grow to go’ switch. 
Cortactin (CTTN gene) has also been suggested as a potential metastatic driver from the 11q13.3 
band, mediating an epithelial-to-mesenchymal switch through interactions with cytoskeletal 
components (Patel et al., 1998; van Rossum et al., 2006; Rothschild et al., 2006; Luo et al., 2006; 
Gibcus et al., 2008; Yamada et al., 2010). Regardless of mechanism, our results suggest that 
ANO1 copy number gain could act as a strong predictive marker for HPSCC tumours with a high 
risk of nodal metastasis. Crucial to this supposition would be further studies examining local versus 
nodal (or distant metastatic) recurrence across the ANO1 gain positive patients, or re-staging in 
those ANO1 gain positive patients with node negative disease at presentation. 
 
Interestingly, our results do not support a similar role for ANO1/CCND1 copy number gain in nodal 
metastasis in the HPV/p16 negative OPSCC subgroup. It is plausible that the relevant pathways 
may be affected downstream of the 11q13.3 genes themselves, or by different means (epigenetic 
change, mutation) in OPSCC. However this finding could also indicate that the requirements for 
lymphatic invasion and cell spread differ between the mucosa of the oropharynx and hypopharynx, 
thus altering the selection pressures between the two tumour types and resulting in different 
molecular signatures observed in our study. 
 
A mutually exclusive association between 11q13.3 amplification, smoking history and HPV/p16 has 
been widely reported across many populations (Smeets et al., 2006; Ragin et al., 2006; Klussmann 
et al., 2009; Lechner et al., 2013; Seiwert et al., 2015). Our findings are consistent with this model, 
observing again an inverse relationship between HPV/p16 status and the presence of CCND1 and 
ANO1 copy number gains. The pathogenic basis for this genetic distinction likely stems from the 
selection pressure to overcome the restriction point of G1-to-S cell cycle control in cancer cells. 
Smoking/alcohol-associated HNSCCs are frequently characterised by amplification and over-
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expression of Cyclin D1, often complimented by loss of the G1 restriction point Cyclin Kinase 
Inhibitor p16INK4A, which itself binds and inactivates the Cyclin D1/CDK4 complex. HPV-
associated tumours predominantly preserve p16INK4A, and (as observed here) typically preserve 
normal CCND1 copy number. This reflects the actions of viral oncogene E7 in HPV-associated 
tumours, which binds and inactivates pRB (releasing the pro-proliferative E2F transcription 
activating factor) effectively committing cells to S phase down-stream of Cyclin D1 / CDK4 / 
p16INK4A changes, and bypassing the selection pressure to alter Cyclin D1 or p16INK4A found in 
smoking/alcohol-associated tumours. 
 
Of course, this does not preclude the co-existence of HPV and 11q13.3 amplification in HNSCC, 
as observed in one patient sample in our study (nor the presence of HPV and the absence of p16, 
also observed). In some cases, the presence of HPV (whether as ‘by-stander’ infection or co-factor) 
may not be the primary driver of tumour progression as it is in those HPV/p16 ‘dual positive’ 
patients, and pre-existing genetic changes (TP53 mutation, p16INK4A loss, or even 11q13.3 
changes) may predominate over the actions of HPV E6 and E7. Such instances are most likely in 
those HPV-positive patients with a smoking history, as suggested in other studies (Keck et al., 
2015) and supported by our own findings. Although these (and other) relationships are somewhat 
dependent on definitions and detection of HPV/p16 status (in our study grouping all patients 
without a combined HPV-positive result and p16-positive result) and are often only possible in the 
diminishing groups of patients with both HPV and smoking histories, the use of both p16 IHC and 
direct HPV detection adds validity to these observations, and of the distinct aetiological groups 
existing within our population. 
  
The well-established inverse relationship between HPV and 11q13.3 amplification raises another 
intriguing question relating to molecular-pathological relationships in HNSCC. In our study 
population, HPV disease almost universally presents with nodal metastasis (some times in the 
absence of identifiable primary) but these patients are almost universally devoid of 11q13.3 
amplification. Given that, by default, 11q13.3 amplification cannot be contributing to nodal 
metastasis in HPV-associated disease, what factors (host or viral) are driving a ‘metastatic switch’ 
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in HPV/p16 positive patients? In the context of our findings that ANO1/CCND1 gains do not appear 
to influence a ‘small primary / node positive’ pathological pattern in HPV/p16 negative OPSCCs, it 
would be interesting to explore whether the specific selection pressures or molecular changes 
underpinning nodal metastasis are convergent across the HPV/p16 positive and negative OPSCC 
groups (thereby presenting common biomarkers or future therapeutic targets for metastatic 
disease across both patient groups), or whether yet more distinct molecular changes underpin this 
critical disease change in the two patient groups. 
 
From a certain perspective, HPV can be considered a ‘protective’ factor over host genome integrity 
– by virtue of the ‘supra-genomic’ mechanisms of action of E6 and E7 in enabling unfettered cell 
proliferation, HPV can essentially supersede two critical selection pressures in tumour cells (knock 
out of p53; over-ride of G1-to-S restriction point). In so doing, HPV-associated tumours are more 
likely to maintain functional p53 (and p16INK4a), providing at least the potential for a degree of 
genomic integrity, which may well underlie the better patient outcomes observed in HPV-
associated disease. However, as demonstrated in our study, the presence of HPV alone is not 
sufficient for malignant progression, with TP63 and PIK3CA copy number gains detectable at 
equivalent rates in HPV and smoking/alcohol-associated OPSCCs. In addition to exploring the 
factors associated with nodal metastasis in HPV-associated tumours (as discussed above), it 
would be of great interest to assess whether E6 and/or E7 expression at a protein level (and other 
factors linked to this like viral genome integration) correlate to patterns of copy number gain or 
other mutations, or indeed to patient outcomes. 
 
PIK3CA (encoding the catalytic p110 subunit of PI3 kinase complex) is a well-established 
oncogene - mutated, amplified and over-expressed across many common cancers, p110alpha can 
drive proliferation and survival in tumour cells via activation of central mediator AKT and other 
down-stream elements of the pathway. NGS projects have consistently found PIK3CA gene 
changes spanning both HPV-associated and smoking/alcohol-associated HNSCC groups (with 
many reporting increased prevalence of PIK3CA change in HPV-associated disease) (Nichols et 
al., 2013; Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 2015), suggesting 
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a possible common evolutionary requirement for maintaining proliferation or de-differentiation 
across a majority of HNSCCs. Interestingly, while we did observe PIK3CA gains across both the 
HPV/p16-positive and HPV/p16-negative OPSCCs at rates consistent with the literature, PIK3CA 
copy number gain was a rare event in our HPSCC population. This could suggest HPSCCs evolve 
with different pro-proliferative signalling mutations, or that the involvement of the PI3 kinase 
pathway in HPSCCs occurs via mechanisms other than copy number gain or amplification. The 
lack of association between PIK3CA (or TP63) and pathological stage in our study, combined with 
the relatively equal distribution across HPV-associated and smoking/alcohol-associated disease 
add weight to the supposition that these genes have a fundamental role in maintaining proliferation 
(rather than, for example, driving metastasis) in the subset of tumours harbouring these changes. 
 
Technical differences could potentially contribute to the differences observed in PIK3CA copy 
number gain frequency between our study and previous work. However this seems unlikely owing 
to a number of observations and measures. First, in an effort to counter any effect of variability of 
tumour-to-stroma in our samples, and to reduce any effect of different sample age on results, we 
selected samples for final analysis based on spectrophotometric quality and quantity of nucleic 
acid, and performed our analysis based on presence or absence of ‘large’ detectable copy number 
gains (i.e. more than 4 copies of a target marker, calculated using the ddCt method). Second, our 
observation of the well-recognised inverse relationship between HPV/p16 and 11q13.3 copy 
number gains, together with the strong statistical correlation of CCND1 and ANO1 gains together 
in the majority of gain-positive samples provides further re-assurance that our PCR assay results 
reflect plausible copy number changes in the extracted tumour DNA. 
 
The basis for the reported poor outcomes of HPSCC patients is likely to be multi-factorial. 
Outcomes may relate to i.) the anatomical position of this tumour subset, ii.) the often cited 
extensive co-morbidity, and iii.) the lower burden of HPV associated disease (Ernoux-Neufcoeur et 
al., 2011; Joo et al., 2013; Wendt et al., 2014; Castellsague et al., 2016) in this patient group. In 
addition to demonstrating the low prevalence of HPV in this patient subset, our results show that 
the molecular signatures of our HPSCC patients are significantly different to those of our OPSCC 
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patients at specific genes. Whether these differences (or other molecular differences not explored 
in our study) underlie prognosis in our patients remains unclear. Evidence for a prognostic effect of 
11q13.3 amplification in HNSCC is inconsistent (Ruiz et al., 2012; Muller et al., 1997; Klussman et 
al., 2009; Hermsen et al., 2005; Rodrigo et al., 2000; Namazie et al., 2002; Ashman et al., 2003; 
Wreesmann et al., 2004; Xavier et al., 2012), but recent meta-analysis identified ANO1 (along with 
FADD) as the strongest potential host prognostic biomarkers across HNSCC (Reddy et al., 2016). 
 
Our study focussed exclusively on the detection of copy number gains of specific genes in the 
11q13.3 and 3q sites, however several other genetic changes have been proposed to occur 
synchronously with these changes in HNSCC (as reviewed in Gollin 2014). Co-amplification 
between 11q13.3 and 11q22 has recently been confirmed in NGS data (Cancer Genome Atlas 
Network, 2015), proposed to stem from a selective pressure for amplification and over-expression 
of both FADD (11q13.3) and BIRC2 (11q22) in HNSCC, with likely anti-apoptotic effect. In other 
studies, 11q13.3 amplification has been associated with deletions of regions distal to 11q14 
(Bockmuhl et al., 2002; Parikh et al., 2007), and deletions of 3p regions, each likely to involve loss 
of tumour suppressor genes which may contribute to disease progression and clinical outcome. 
Such associations remain under-reported in HPSCC tumours, and future studies in our sample 
population would benefit from more comprehensive analysis of the effects of combined gain/loss 
patterns. Given the high frequency of ANO1/CCND1 copy number gain in HPSCC, it would also be 
interesting to explore whether tumours from this anatomical site fall predominantly within the basal 
molecular subtype (where 11q13.3 amplification is observed most frequently in other HNSCCs, as 
described in Cancer Genome Atlas Network, 2015), and whether this could influence treatment 
choice in future. 
 
Larger scale studies with sample sizes great enough to control for pathological stage, co-morbidity 
and treatment modality would be of great value in any future exploration of the apparent molecular-
pathogenic differences between our HPV/p16 negative HPSCC and OPSCC patient groups. Given 
the strong link with nodal metastasis, future studies of tumour recurrence and outcomes in HPSCC 
in relation to Ano1 and Cyclin D1 amplification and over-expression (and other genes in the 
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11q13.3 region) are also merited. This could form the basis for a (non-HPV) risk stratification 
process – with a combination of markers (potentially including ANO1) used to identify those 
patients with high risk of metastatic disease, thereby altering their management to include systemic 
therapy, surgical nodal clearance, or more intensive follow-up or re-staging. 
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Figure 1. Frequency of copy number gains at target genes across HNSCC patients grouped by i.) anatomical 
tumour site (HPSCC n=48; OPSCC n=52), ii.) HPV/p16 status (HPV/p16 negative n=47; HPV/p16 positive 
n=27) and iii.) anatomical tumour site in HPV/p16 negative tumours (HPV/p16 negative HPSCC n=47; 
HPV/p16 negative OPSCC n=27).  
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Figure 2. Nodal metastasis and T stage are significantly associated with ANO1 copy number gains in 
HPV/p16 negative HPSCC, but not in HPV/p16 negative OPSCC tumours. ANO1 copy number gains were 
significantly more frequent in HPV/p16 negative HPSCC tumours with lymph node metastasis (i, p=0.031), 
smaller or less invasive tumours as determined by T stage (ii, p=0.022), and in those tumours presenting as 
both node-positive and T1-3 at presentation (iii, p=0.010). ANO1 copy number gain was not significantly 
different across pathological stage in HPV/p16 OPSCC tumours. * indicates statistically significant difference 
(Pearson’s Chi Square test).  
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Clinico-pathologic characteristic 
  
HPSCC 
(n=48) 
OPSCC 
(n=52) p value 
Age (mean)   65.92 62.83 0.137 
Sex 
  
Male 39 (81.3) 24 (46.2) <0.001 
Female 9 (18.8) 28 (53.8)   
Smoking 
  
  
  
Never smoker 7 (14.6) 11 (21.2) 0.002* 
Past smoker 9 (18.8) 24 (46.2)   
Current smoker 31 (64.6) 16 (30.8)   
nk 1 (2.1) 1 (1.9)   
Drinking 
  
  
  
  
Never drinker 4 (8.3) 9 (17.3) 0.012* 
Social drinker 19 (39.6) 28 (53.8)   
Past heavy drinker 5 (10.4) 0 (0)   
Current heavy drinker 17 (35.4) 12 (23.1)   
nk 3 (6.3) 3 (5.8)   
Stage 
  
  
  
T1-3 25 (52.1) 32 (61.5) 0.34 
T4 23 (47.9) 20 (38.5)   
T1-3/Node positive 19 (39.6) 23 (44.2) 0.638 
Node positive 33 (68.8) 40 (76.9)   
HPV/p16 status 
  
  
  
  
HPV negative/p16 
negative 
47 (97.9) 21 (42.0) <0.001* 
HPV negative/p16 
positive 
0 (0.0) 2 (4.0)   
HPV positive/p16 
negative 
0 (0.0) 4 (8.0)   
HPV positive/p16 
positive 
1 (2.1) 23 (46.0)   
nk 0 (0) 1 (1.9)   
Copy number gain 
  
  
  
PIK3CA 3 (6.3) 14 (26.9) 0.006 
TP63 9 (18.8) 10 (19.2) 0.951 
CCND1 27 (56.3) 12 (23.1) <0.001 
ANO1 27 (56.3) 9 (17.3) <0.001 
 
Table 1. Clinico-pathologic characteristics of hypopharyngeal squamous cell carcinoma 
(HPSCC) and oropharyngeal squamous cell carcinoma (OPSCC) patients in the study. 
Values shown are number (% column total); nk – not known. TNM – as defined by UICC TNM 
Classification (6
th
 edition); T – tumour size, N – lymph node status. P value indicates significance 
using Pearson’s Chi-square test; 
f
 indicates Fisher’s Exact test; 
t
 indicates Student’s t-test. * 
indicates a p-value calculated from grouping patients together (never & social vs ex & current 
heavy; never & ex smoker vs current smoker; HPV/p16 positive vs HPV/p16 negative as defined 
in methods). 
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Clinico-pathologic characteristic 
  
HPV negative/ 
p16 negative (n=68) 
HPV negative/ 
p16 positive (n=2) 
HPV positive/ 
p16 negative (n=4) 
HPV positive/ 
p16 positive (n=24)   
HPV/p16  
negative (n=74) 
HPV/p16  
positive (n=24) p value 
Age (mean)  - -  -  -    65.2 61.5 0.173 
Sex 
  
Male 49 (72.1) 1 (50.0) 0 (0.0) 13 (54.2)   50 (67.6) 13 (54.2) 0.234 
Female 19 (27.9) 1 (50.0) 4 (100.0) 11 (45.8)   24 (32.4) 11 (45.8)   
Smoking 
  
  
Never smoker 9 (13.6) 0 (0.0) 0 (0.0) 8 (33.3)   9 (12.5) 8 (33.3) <0.001* 
Past smoker 16 (24.2) 0 (0.0) 1 (25.0) 15 (62.5)   17 (23.6) 15 (62.5)   
Current smoker 41 (62.1) 2 (100.0) 3 (75.0) 1 (4.2)   46 (63.9) 1 (4.2)   
Drinking 
  
  
  
Never drinker 6 (9.2) 0 (0.0) 0 (0.0) 6 (27.3)   6 (8.6) 6 (27.3) 0.002* 
Social drinker 31 (47.7) 0 (0.0) 1 (33.3) 14 (63.6)   32 (45.7) 14 (63.6)   
Past heavy drinker 5 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)   5 (7.1) 0 (0.0)   
Current heavy drinker 23 (35.4) 2 (100.0) 2 (66.7) 2 (9.1)   27 (38.6) 2 (9.1)   
Smoking & Drinking Current smoker & drinker 40 (63.5) 2 (100.0) 2 (66.7) 1 (4.5)   44 (64.7) 1 (4.5) 0.005 
Stage 
  
  
  
T1-3 35 (51.5) 2 (100.0) 1 (25.0) 18 (75.0)   38 (51.4) 18 (75.0) 0.034 
T4 33(48.5) 0 (0.0) 3 (75.0) 6 (25.0)   36 (48.6) 6 (25.0)   
Node positive 44 (64.7) 2 (100.0) 3 (75.0) 23 (95.8)   49 (66.2) 23 (95.8) 0.004 
T1-3/Node positive 22 (32.4) 2 (100.0) 1 (25.0) 17 (70.8)   25 (33.8) 17 (70.8) 0.001 
Copy number gain 
  
  
  
PIK3CA 7 (10.3) 1 (50.0) 3 (75.0) 6 (25.0)   11 (14.9) 6 (25.0) 0.255 
TP63 14 (20.6) 0 (0.0) 1 (25.0) 4 (16.7)   15 (20.3) 4 (16.7) 0.698 
CCND1 34 (50.0) 1 (50.0) 2 (50.0) 1 (4.2)   37 (50.0) 1 (4.2) <0.001 
ANO1 32 (47.1) 1 (50.0) 2 (50.0) 0 (0.0)   35 (47.3) 0 (0.0) <0.001 
 
Table 2. Clinico-pathologic characteristics of patients grouped by HPV and p16 status in the study. Values shown are number (% column total); nk – not 
known. TNM – as defined by UICC TNM Classification (6th edition); T – tumour size, N – lymph node status. P value indicates significance using Pearson’s Chi-
square test; f indicates Fisher’s Exact test; t indicates Student’s t-test. * indicates a p-value calculated from grouping patients together (never & social vs ex & current 
heavy; never & ex smoker vs current smoker; HPV/p16 positive vs HPV/p16 negative as defined in methods). 
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Clinico-pathologic characteristic 
  
HPV/p16 negative 
HPSCC (n=47) 
HPV/p16 negative 
OPSCC (n=27) p value 
Age (mean) 66.1 63.7 0.327t 
Sex 
  
Male 38 (80.9) 12 (44.4) 0.001 
Female 9 (19.1) 15 (55.6)   
Smoking 
  
  
Never smoker 7 (15.2) 2 (7.7) 0.755 
Past smoker 9 (19.6) 8 (30.8)   
Current smoker 30 (65.2) 16 (61.5)   
Drinking 
  
  
  
Never drinker 4 (9.1) 2 (7.7) 0.66 
Social drinker 19 (43.2) 13 (50.0)   
Past heavy drinker 5 (11.4) 0 (0.0)   
Current heavy drinker 16 (36.4) 11 (42.3)   
Smoking & Drinking Current smoker & drinker 29 (67.4) 15 (60.0) 0.665 
Stage 
  
  
  
T1-3 24 (51.1) 14 (51.9) 0.948 
T4 23 (48.9) 13 (48.1)   
Node positive 32 (68.1) 17 (63.0)   
T1-3/Node positive 18 (38.3) 7 (25.9) 0.279 
Copy number gain 
  
  
  
PIK3CA 3 (6.4) 8 (29.6) 0.010f 
TP63 9 (19.1) 6 (22.2) 0.752 
CCND1 27 (57.4) 10 (37.0) 0.091 
ANO1 27 (57.4) 8 (29.6) 0.021 
 
Table 3. Clinico-pathologic characteristics of HPV/p16 negative subsets of HPSCC and OPSCC patients in the study. Values shown are 
number (% column total); nk – not known. TNM – as defined by UICC TNM Classification (6
th
 edition); T – tumour size, N – lymph node status. P value 
indicates significance using Pearson’s Chi-square test; 
f
 indicates Fisher’s Exact test; 
t
 indicates Student’s t-test. * indicates a p-value calculated from 
grouping patients together (never & social vs ex & current heavy; never & ex smoker vs current smoker; HPV/p16 positive vs HPV/p16 negative as 
defined in methods). 
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Clinico-pathologic characteristic 
  
PIK3CA p TP63 p CCND1 p ANO1 p 
Sex 
  
Male 3 (7.7) 0.528f 7 (17.9) 0.767 24 (61.5) 0.122f 23 (59.0) 0.335f 
Female 0 (0.0) 
 
2 (22.2) 
 
3 (33.3) 
 
4 (44.4) 
 
Smoking 
  
Ex or never smoker 2 (12.5) 0.218f 3 (18.8) 0.96 9 (56.3) 0.927 8 (50.0) 0.598 
Current smoker 1 (3.2) 
 
6 (19.4) 
 
17 (54.8) 
 
18 (58.1) 
 
Drinking 
  
Never or social drinker 1 (4.3) 0.524f 4 (17.4) 0.655 10 (43.5) 0.175 11 (47.8) 0.449 
Ex heavy or current heavy drinker 2 (9.1) 
 
5 (22.7) 
 
14 (63.6) 
 
13 (59.1) 
 
Smoking & drinking Current smoker & drinker 1 (3.3) 0.264f 6 (20.0) 0.641f 15 (51.7) 0.919 16 (55.2) 0.592 
Stage 
  
T1-3 0 (0.0) 0.102f 7 (28.0) 0.089f 17 (68.0) 0.087 18 (72.0) 0.022 
T4 3 (13.0) 
 
2 (8.7) 
 
10 (43.5) 
 
9 (39.1) 
 
Node positive 1 (3.0) 0.172f 7 (21.2) 0.415f 21 (63.6) 0.126 22 (66.7) 0.031 
T1-3/Node positive 0 (0.0) 0.211f 6 (31.6) 0.073 14 (73.7) 0.049 15 (78.9) 0.011 
HPV/p16 status 
  
  
  
HPV negative/p16 negative 3 (6.4) 0.938f 9 (19.1) 0.813f 27 (57.4) 0.438f 27 (57.4) 0.438f 
HPV negative/p16 positive - 
 
- 
 
- 
 
- 
 
HPV positive/p16 negative - 
 
- 
 
- 
 
- 
 
HPV positive/p16 positive 0 (0.0) 
 
0 (0.0) 
 
0 (0.0) 
 
0 (0.0) 
 
 
Table 4. Frequency and association of gene copy number gains across demographic, risk factor and pathological features of HPSCC 
patients. Values shown are number (% row total). TNM – as defined by UICC TNM Classification (6
th
 edition); T – tumour size, N – lymph node 
status. P value indicates significance using Pearson’s Chi-square test; 
f
 indicates Fisher’s Exact test. 
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Clinico-pathologic characteristic 
  PIK3CA p value TP63 p value CCND1 p value ANO1 p value 
Sex 
  
Male 6 (25.0) 0.772 6 (25.0) 0.266f 5 (20.8) 0.722 4 (16.7) 0.602f 
Female 8 (28.6)   4 (14.3)   7 (25.0)   5 (17.9)   
Smoking 
  
Ex or never smoker 7 (20.0) 0.079f 7 (20.0) 0.619f 5 (14.3) 0.028f 3 (8.6) 0.020f 
Current smoker 7 (50.0)   3 (18.8)   7 (43.8)   6 (37.5)   
Drinking 
  
Never or social drinker 8 (21.6) 0.323f 5 (13.5) 0.300f 7 (18.9) 0.254f 5 (13.5) 0.300f 
Ex heavy or current heavy drinker 4 (33.3)   3 (25.0)   4 (33.3)   3 (25.0)   
Smoking & drinking Current smoker & drinker 6 (40.0) 0.106f 2 (13.3) 0.515f 6 (40.0) 0.066f 5 (33.3) 0.051f 
Stage 
  
  
  
T1-3 11 (34.4) 0.125 7 (21.9) 0.408f 9 (28.1) 0.228f 6 (18.8) 0.519f 
T4 3 (15.0)   3 (15.0)   3 (15.0)   3 (15.0)   
Node positive 10 (25.0) 0.409f 8 (20.0) 0.582f 7 (17.5) 0.091f 6 (15.0) 0.340f 
T1-3/Node positive 8 (34.8) 0.255 5 (21.7) 0.475 4 (17.4) 0.386 3 (13.0) 0.366f 
HPV/p16 status 
  
  
  
  
  
HPV negative/p16 negative 4 (19.0)   5 (23.8)   7 (33.3)   5 (23.8)   
HPV negative/p16 positive 1 (50.0)   0 (0.0)   1 (50.0)   1 (50.0)   
HPV positive/p16 negative 3 (75.0)   1 (25.0)   2 (50.0)   2 (50.0)   
HPV positive/p16 positive 6 (26.1)   4 (17.4)   1 (4.3)   0 (0.0)   
HPV/p16 negative 8 (29.6) 0.781 6 (22.2) 0.474 10 (37.0) 0.005 8 (29.6) 0.004f 
HPV/p16 positive 6 (26.1)   4 (17.4)   1 (4.3)   0 (0.0)   
 
Table 5. Frequency and association of gene copy number gains across demographic, risk factor and pathological features of OPSCC 
patients. Values shown are number (% row total). TNM – as defined by UICC TNM Classification (6
th
 edition); T – tumour size, N – lymph node 
status. P value indicates significance using Pearson’s Chi-square test; 
f
 indicates Fisher’s Exact test. 
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Clinico-pathologic characteristic 
  PIK3CA p value TP63 p value CCND1 p value ANO1 p value 
Sex 
  
Male 3 (25.0) 0.484f 3 (25.0) 0.557f 5 (41.7) 0.481f 4 (33.3) 0.516f 
Female 5 (33.3)   3 (20.0)   5 (33.3)   4 (26.7)   
Smoking 
  
Ex or never smoker 1 (10.0) 0.081f 3 (30.0) 0.420f 3 (30.0) 0.391f 2 (20.0) 0.312f 
Current smoker 7 (43.8)   3 (18.8)   7 (43.8)   6 (37.5)   
Drinking 
  
Never or social drinker 4 (26.7) 0.655f 3 (20.0) 0.654f 5 (33.3) 0.598f 4 (26.7) 0.655f 
Ex heavy or current heavy drinker 3 (27.3)   2 (18.2)   4 (36.4)   3 (27.3)   
Smoking & drinking Current smoker & drinker 6 (40.0) 0.118f 2 (13.3) 0.301f 6 (40.0) 0.470f 5 (33.3) 0.399f 
Stage 
  
  
  
T1-3 5 (35.7) 0.385f 3 (21.4) 0.638f 7 (50.0) 0.147f 5 (35.7) 0.385f 
T4 3 (23.1)   3 (23.1)   3 (23.1)   3 (23.1)   
Node positive 5 (29.4) 0.651f 4 (23.5) 0.613f 6 (35.3) 0.563f 6 (35.3) 0.349f 
T1-3/Node positive 3 (42.9) 0.332f 1 (14.3) 0.498f 3 (42.9) 0.525f 3 (42.9) 0.332f 
 
Table 6. Frequency and association of gene copy number gains across demographic, risk factor and pathological features of HPV/p16 
negative OPSCC patients. Values shown are number (% row total). TNM – as defined by UICC TNM Classification (6
th
 edition); T – tumour size, N – 
lymph node status. P value indicates significance using Pearson’s Chi-square test; 
f
 indicates Fisher’s Exact test. 
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Supplemental Material S1 
Gene Symbol (name) Genome location (co-ordinates*) 
PIK3CA (PI3 kinase alpha) 3q26 (179148114...179235137) 
TP63 (p63) 3q28 (189631160...189897279) 
CCND1 (Cyclin D1) 11q13 (69641105...69654474) 
ANO1 (Anoctamin 1) 11q13.3 (69985875...70189545) 
EIF2B4 (Eukaryotic Initiation Factor 2B 
delta) 
2p23.3 (27364352...27370457) 
Target & reference genes; *co-ordinates correspond to Homo sapiens reference genome 
Assembly GRCh38.p2 
PRIMER SEQUENCE ANNEAL 
TEMP (
o
C) 
LENGTH PRODUCT 
SIZE 
FINAL qPCR 
CONC 
gPIK3CAleft TGATGGCTGCTGACTTACCA 59 20 
91 
300nM 
gPIK3CAright GTGGCAAACTTCACTGTCGT 59 20 300nM 
gTP63left CAAGCATAGCACGACAGTCC 59 20 
109 
300nM 
gTP63right CTGTACTACTCTCGCCTGGG 59 20 300nM 
gCCND1left AGCCTGTAACGAACTCCCAA 59 20 
135 
300nM 
gCCND1right GCATTTCCCCAGACGTCATC 59 20 300nM 
gANO1left AGTAAGTGGGGAATGGGGTG 59 20 
122 
300nM 
gANO1right CCCCTGGCTTTTCTGGTAGA 59 20 300nM 
gEIF2Bleft AACCAGAGCGTCAACAGGTA 59 20 
126 
300nM 
gEIF2Bright ACTACTCTGACCCAAGCACC 59 20 300nM 
Target & reference primers, amplicons & optimum qPCR conditions 
Cycles Temperature (oC) / duration (second) 
1 95 / 120 
40 
95 / 20 
59 / 20 
72 / 20
F
 
1 55-95 / 300* 
qPCR reaction conditions – final reaction conditions were 1 X Maxima SYBR Green 
Master Mix (Thermo), 300-500nM forward primer, 300-500nM reverse primer (see above for 
primer-specific final concentrations), 2.5ng DNA template (tumour DNA, tonsil DNA or 
pooled human genomic DNA (Promega)). FFluorescence read at end of each extension step; 
* varying temperature fluorescence read throughout for melt curve analysis. 
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